Latest Articles
-
Here’s A Better Pick Over Abbott Stock
We think that Teva stock (NYSE: TEVA) currently is a better pick compared to its industry peer, Abbott stock (NYSE: ABT), given its comparatively lower valuation and better prospects. TEVA stock is trading at 0.6x trailing revenues compared ...
-
This Medical Devices Company Is A Better Pick Over Abbott Stock
We think that Stryker Corp. stock (NYSE: SYK) currently is a better pick compared to its industry peer, Abbott stock (NYSE: ABT), despite it being the more expensive of the two, trading at 6.1x trailing revenues compared to 5.1x for Abbott. ...
-
This Healthcare Company Is A Better Pick Over Abbott Stock
We think that Thermo Fisher Scientific stock (NYSE: TMO) currently is a better pick compared to Abbott Labs stock (NYSE: ABT), with a similar market capitalization in the healthcare sector, despite its comparatively expensive valuation. ABT stock...
-
Should You Buy Abbott Stock After Its Recent Fall?
The stock price of Abbott (NYSE: ABT) has seen a fall of 7% in a month, while it declined 4% in a week. This can largely be attributed to its recent voluntary recall of three types of baby formula – Similac, Alimentum, and EleCare –...
-
What’s The Outlook For Covid-19 Testing Stocks As Omicron Wave Fades
Our indicative theme on Covid-19 Testing Stocks – which includes companies that produce or carry out tests for Covid-19 infections – has underperformed considerably thus far in 2022, declining by about 14% year-to-date, compared to the S&...
-
Will Abbott Stock Rise After Its Q4 Results?
Abbott (NYSE:ABT) is scheduled to report its Q4 2021 results on Wednesday, January 26, and we expect it to be below the consensus estimates. A rise in Covid-19 cases in Q4 due to the spread of the Omicron variant likely aided Covid-19 testing d...
-
Why Covid-19 Testing Stocks Are Selling Off Despite Surging Demand
Our indicative theme on Covid-19 Testing Stocks – which includes companies that produce or carry out tests for Covid-19 infections – has underperformed considerably thus far in 2022, declining by about 13% year-to-date, compared to the S&...
-
Forecast Of The Day: Abbott’s Nutritionals Revenue
What? Abbott’s (NYSE:ABT) Nutritionals Revenue has risen from around $7.4 billion in 2019 to about $7.7 billion in 2020. Trefis expects the metric to rise to about $8.4 billion in 2021 and to about $8.7 billion in 2022. Why? We expect g...
-
This Pharma Stock Appears To Be A Better Pick Over Abbott Labs
We think that Eli Lilly stock (NYSE: LLY) currently is a better pick compared to Abbott Labs stock (NYSE: ABT) with similar market capitalization in the healthcare sector, despite Eli Lilly being the more expensive of the two. LLY stock trades a...
-
Will Abbott Stock Rise After Its Q3 Results?
Abbott (NYSE:ABT) is scheduled to report its Q3 2021 results on Wednesday, October 20, and we expect it to be slightly above the consensus estimates, driven by a rise in demand for medical devices as well as its established pharmaceuticals busi...
-
With Covid-19 Cases Falling Again Will Abbott Stock See Higher Levels?
[Updated: Sep 29, 2021] Abbott Stock Decline The stock price of Abbott (NYSE:ABT) has seen a drop of 5% over the last one month (twenty-one trading days). It reached its 52-week high level of around $130 on September 13, before a slight decline ...
-
This Stock Is Likely To Outperform Abbott Laboratories
We think that Dexcom stock (NASDAQ: DXCM) currently is a better pick compared to Abbott stock (NYSE:ABT), despite Dexcom being more expensive of the two. Dexcom trades at about 25x trailing revenues, compared to just 5x for Abbott. Although both...
-
What’s Happening With Abbott Stock?
[Updated: Sep 3, 2021] Abbott Stock Update The stock price of Abbott (NYSE:ABT) has seen a rise of around 20% since early June this year. The company’s Q2 results were comfortably above our as well as the consensus estimates driven by con...
-
Will Abbott Stock Rise Post Q2?
Abbott (NYSE:ABT) is scheduled to report its Q2 2021 results on Thursday, July 22. We expect Abbott to report revenues and earnings above the consensus estimates, driven by continued growth in diagnostics business, along with a rebound in demand ...
-
Will Abbott Stock Continue Its Rally After An 11% Rise In A Month?
The stock price of Abbott Laboratories (NYSE: ABT) has seen an 11% rise over the last twenty-one trading days, while it is up 27% over the last year. Abbott has benefited from a strong demand for Covid-19 testing, which aided its diagnostics b...
